Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients
Year: 2020
Type: article
Abstract: PURPOSE: This study was aimed at comparing the efficacy and tolerability of an arsenic trioxide/bortezomib/ascorbic acid/dexamethasone (ABCD) regimen with efficacy and tolerability of a bortezomib/dexamethasone (BD) regimen in patients with newly diagnosed myeloma. PATIENTS AND METHODS: Fifty-seven and sixty-four patients were treated with the ABCD and BD regimens, respectively. Eligible and agreeable patients received autologous hematopoietic stem cell transplantation followed by consolidation. RESULTS: The response rates (above VGPR) were 74.1% and 32.8% in the ABCD- and BD-treated groups, respectively (P = 0.000). Compared to BD regimen, ABCD regimen significantly improved PFS (P = 0.026) and OS (P = 0.000) in newly diagnosed patients. Patients with a high tumor burden, low or standard risk, and without auto-HSCT seemed to especially benefit compared to the same group with BD regimen. ABCD also showed better tolerability with lower bone marrow suppression (P = 0.026). Furthermore, complete response or near CR after induction therapy was a good prognostic factor for ABCD-associated OS and PFS. CONCLUSION: ABCD is an effective and tolerable regimen compared with BD regimen in newly diagnosed myeloma patients. ABCD regimen could be an economical, effective, and tolerable choice in low- and standard-risk patients.
Source: Cancer Management and Research
DOI: 10.2147/cmar.s212455
Authors: Wensi Qian, Li Wang, Pei Li, Yingwei Hu, Qian Wang, Ke Yi, Min Wu, Yu Xu, Jin Song, Pingping Chen, Hongdi Zhang, Jiexian Ma, Yanhui Xie
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: multiple myeloma, newly diagnosed multiple myeloma, arsenic trioxide, bortezomib, vitamin C, dexamethasone, bortezomib-dexamethasone, induction therapy, consolidation therapy, autologous stem cell transplantation, progression-free survival, overall survival, complete response, myelosuppression, treatment tolerability, prognostic factors
Open Access status: gold
Estimated APC paid: $2,836
Award: G5779830691
OpenAlex ID: W3000698556
